Chronic Urticaria Or Hives - Pipeline Review, H2 2017

Date: October 10, 2017
Pages: 51
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C8A9569E78AEN
Leaflet:

Download PDF Leaflet

Chronic Urticaria Or Hives - Pipeline Review, H2 2017
Chronic Urticaria Or Hives - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2017, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 4, 4 and 3 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Chronic Urticaria Or Hives - Overview
Chronic Urticaria Or Hives - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chronic Urticaria Or Hives - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
Biofrontera AG
ELORAC Inc
Faes Farma SA
Fountain Biopharma Inc
Genentech Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Mycenax Biotech Inc
Novartis AG
Synermore Biologics Co Ltd
Chronic Urticaria Or Hives - Drug Profiles
BF-Derm-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bilastine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cetirizine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cidoxepin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDC-0853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2646264 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ligelizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chronic Urticaria Or Hives - Dormant Projects
Chronic Urticaria Or Hives - Discontinued Products
Chronic Urticaria Or Hives - Product Development Milestones
Featured News & Press Releases
Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada
Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan
Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan
Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN
Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration
Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico
Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil
Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain
Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries
Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Chronic Urticaria Or Hives, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2017
Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H2 2017
Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H2 2017
Chronic Urticaria Or Hives - Pipeline by Fountain Biopharma Inc, H2 2017
Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H2 2017
Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2017
Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H2 2017
Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2017
Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H2 2017
Chronic Urticaria Or Hives - Dormant Projects, H2 2017
Chronic Urticaria Or Hives - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Chronic Urticaria Or Hives, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Biofrontera AG
ELORAC Inc
Faes Farma SA
Fountain Biopharma Inc
Genentech Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Mycenax Biotech Inc
Novartis AG
Synermore Biologics Co Ltd
Skip to top


Chronic Urticaria Or Hives - Pipeline Review, H1 2017 US$ 2,000.00 May, 2017 · 52 pages
Chronic Plaque Psoriasis - Pipeline Review, H1 2015 US$ 2,000.00 Jan, 2015 · 109 pages

Ask Your Question

Chronic Urticaria Or Hives - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: